Loading…
Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years
Treatment for patients > 60 years with classical Hodgkin lymphoma (cHL) is problematic; there is no gold standard, and outcome is poor. Using the Swedish Lymphoma Registry, we analysed all Swedish patients diagnosed with cHL between 2000 and 2014 (N = 2345; median age 42 years; 691 patien...
Saved in:
| Published in: | EJHaem 2021, Vol.2 (3), p.400 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | |
| container_issue | 3 |
| container_start_page | 400 |
| container_title | EJHaem |
| container_volume | 2 |
| creator | Wahlin, Bjoern Engelbrekt Overgaard, Ninja Peterson, Stefan Digkas, Evangelos Glimelius, Ingrid Lagerlöf, Ingemar Johansson, Ann-Sofie Palma, Marzia Hansson, Lotta Linderoth, Johan Goldkuhl, Christina Molin, Daniel |
| description | Treatment for patients > 60 years with classical Hodgkin lymphoma (cHL) is problematic; there is no gold standard, and outcome is poor. Using the Swedish Lymphoma Registry, we analysed all Swedish patients diagnosed with cHL between 2000 and 2014 (N = 2345; median age 42 years; 691 patients were >60 years). The median follow-up time was 6.7 years. Treatment for elderly patients consisted mainly of ABVD or CHOP, and the younger patients were treated with ABVD or BEACOPP (with no survival difference). In multivariable analysis of patients > 60 years, ABVD correlated with better survival than CHOP (p = 0.027), and ABVD became more common over time among patients aged 61-70 years (p = 0.0206). Coinciding with the implementation of FDG-PET/CT, the fraction of advanced-stage disease increased in later calendar periods, also in the older patient group. Survival has improved in cHL patients > 60 years (p = 0.027), for whom ABVD seems superior to CHOP. |
| doi_str_mv | 10.1002/jha2.202 |
| format | article |
| fullrecord | <record><control><sourceid>swepub</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_452094</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_DiVA_org_umu_228661</sourcerecordid><originalsourceid>FETCH-LOGICAL-s1144-b84351b166988130ce157c67ee04432fd31fb191f5827a41605037560af673ce3</originalsourceid><addsrcrecordid>eNqNjEtLw0AUhQdRsNSCP2FWrozOnVcSXJX6qFAQfG3DTTJJp00yIZNQuvKvm2IXrsTVOZzz8RFyCewGGOO3mzXyG874CZlwHUWBBqlPf_VzMvN-w0ZUgNICJuTr1WAV7FxX5TTHHqlraN8Z7GvT9DRzTWba3lPb0KxC722GFV26vNyOS7Wv27Wr8fC-7UxuGspHd8AZyGtauGzwtikPxhZ7O_o8xdLk9Krs7zSje4OdvyBnBVbezI45JR-PD--LZbB6eXpezFeBB5AySCMpFKSgdRxFIFhmQIWZDo1hUgpe5AKKFGIoVMRDlKCZYiJUmmGhQ5EZMSXBj9fvTDukSdvZGrt94tAmx2k7NpNIxVks_-Tv7ec8cV2ZDPWQcB5pDf_jKzvyLFZaiW9Yo4LG</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged &gt;60 years</title><source>Open Access: Wiley-Blackwell Open Access Journals</source><source>PubMed Central</source><creator>Wahlin, Bjoern Engelbrekt ; Overgaard, Ninja ; Peterson, Stefan ; Digkas, Evangelos ; Glimelius, Ingrid ; Lagerlöf, Ingemar ; Johansson, Ann-Sofie ; Palma, Marzia ; Hansson, Lotta ; Linderoth, Johan ; Goldkuhl, Christina ; Molin, Daniel</creator><creatorcontrib>Wahlin, Bjoern Engelbrekt ; Overgaard, Ninja ; Peterson, Stefan ; Digkas, Evangelos ; Glimelius, Ingrid ; Lagerlöf, Ingemar ; Johansson, Ann-Sofie ; Palma, Marzia ; Hansson, Lotta ; Linderoth, Johan ; Goldkuhl, Christina ; Molin, Daniel</creatorcontrib><description>Treatment for patients &amp;gt; 60 years with classical Hodgkin lymphoma (cHL) is problematic; there is no gold standard, and outcome is poor. Using the Swedish Lymphoma Registry, we analysed all Swedish patients diagnosed with cHL between 2000 and 2014 (N = 2345; median age 42 years; 691 patients were &amp;gt;60 years). The median follow-up time was 6.7 years. Treatment for elderly patients consisted mainly of ABVD or CHOP, and the younger patients were treated with ABVD or BEACOPP (with no survival difference). In multivariable analysis of patients &amp;gt; 60 years, ABVD correlated with better survival than CHOP (p = 0.027), and ABVD became more common over time among patients aged 61-70 years (p = 0.0206). Coinciding with the implementation of FDG-PET/CT, the fraction of advanced-stage disease increased in later calendar periods, also in the older patient group. Survival has improved in cHL patients &amp;gt; 60 years (p = 0.027), for whom ABVD seems superior to CHOP.</description><identifier>ISSN: 2688-6146</identifier><identifier>EISSN: 2688-6146</identifier><identifier>DOI: 10.1002/jha2.202</identifier><language>eng</language><subject>classical Hodgkin lymphoma ; older patients ; population-based ; survival ; treatment</subject><ispartof>EJHaem, 2021, Vol.2 (3), p.400</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-209565$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-228661$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:235844675$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Wahlin, Bjoern Engelbrekt</creatorcontrib><creatorcontrib>Overgaard, Ninja</creatorcontrib><creatorcontrib>Peterson, Stefan</creatorcontrib><creatorcontrib>Digkas, Evangelos</creatorcontrib><creatorcontrib>Glimelius, Ingrid</creatorcontrib><creatorcontrib>Lagerlöf, Ingemar</creatorcontrib><creatorcontrib>Johansson, Ann-Sofie</creatorcontrib><creatorcontrib>Palma, Marzia</creatorcontrib><creatorcontrib>Hansson, Lotta</creatorcontrib><creatorcontrib>Linderoth, Johan</creatorcontrib><creatorcontrib>Goldkuhl, Christina</creatorcontrib><creatorcontrib>Molin, Daniel</creatorcontrib><title>Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged &gt;60 years</title><title>EJHaem</title><description>Treatment for patients &amp;gt; 60 years with classical Hodgkin lymphoma (cHL) is problematic; there is no gold standard, and outcome is poor. Using the Swedish Lymphoma Registry, we analysed all Swedish patients diagnosed with cHL between 2000 and 2014 (N = 2345; median age 42 years; 691 patients were &amp;gt;60 years). The median follow-up time was 6.7 years. Treatment for elderly patients consisted mainly of ABVD or CHOP, and the younger patients were treated with ABVD or BEACOPP (with no survival difference). In multivariable analysis of patients &amp;gt; 60 years, ABVD correlated with better survival than CHOP (p = 0.027), and ABVD became more common over time among patients aged 61-70 years (p = 0.0206). Coinciding with the implementation of FDG-PET/CT, the fraction of advanced-stage disease increased in later calendar periods, also in the older patient group. Survival has improved in cHL patients &amp;gt; 60 years (p = 0.027), for whom ABVD seems superior to CHOP.</description><subject>classical Hodgkin lymphoma</subject><subject>older patients</subject><subject>population-based</subject><subject>survival</subject><subject>treatment</subject><issn>2688-6146</issn><issn>2688-6146</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqNjEtLw0AUhQdRsNSCP2FWrozOnVcSXJX6qFAQfG3DTTJJp00yIZNQuvKvm2IXrsTVOZzz8RFyCewGGOO3mzXyG874CZlwHUWBBqlPf_VzMvN-w0ZUgNICJuTr1WAV7FxX5TTHHqlraN8Z7GvT9DRzTWba3lPb0KxC722GFV26vNyOS7Wv27Wr8fC-7UxuGspHd8AZyGtauGzwtikPxhZ7O_o8xdLk9Krs7zSje4OdvyBnBVbezI45JR-PD--LZbB6eXpezFeBB5AySCMpFKSgdRxFIFhmQIWZDo1hUgpe5AKKFGIoVMRDlKCZYiJUmmGhQ5EZMSXBj9fvTDukSdvZGrt94tAmx2k7NpNIxVks_-Tv7ec8cV2ZDPWQcB5pDf_jKzvyLFZaiW9Yo4LG</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Wahlin, Bjoern Engelbrekt</creator><creator>Overgaard, Ninja</creator><creator>Peterson, Stefan</creator><creator>Digkas, Evangelos</creator><creator>Glimelius, Ingrid</creator><creator>Lagerlöf, Ingemar</creator><creator>Johansson, Ann-Sofie</creator><creator>Palma, Marzia</creator><creator>Hansson, Lotta</creator><creator>Linderoth, Johan</creator><creator>Goldkuhl, Christina</creator><creator>Molin, Daniel</creator><scope>ADTPV</scope><scope>AOWAS</scope><scope>DG8</scope><scope>ADHXS</scope><scope>D8T</scope><scope>D93</scope><scope>ZZAVC</scope></search><sort><creationdate>2021</creationdate><title>Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged &gt;60 years</title><author>Wahlin, Bjoern Engelbrekt ; Overgaard, Ninja ; Peterson, Stefan ; Digkas, Evangelos ; Glimelius, Ingrid ; Lagerlöf, Ingemar ; Johansson, Ann-Sofie ; Palma, Marzia ; Hansson, Lotta ; Linderoth, Johan ; Goldkuhl, Christina ; Molin, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-s1144-b84351b166988130ce157c67ee04432fd31fb191f5827a41605037560af673ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>classical Hodgkin lymphoma</topic><topic>older patients</topic><topic>population-based</topic><topic>survival</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wahlin, Bjoern Engelbrekt</creatorcontrib><creatorcontrib>Overgaard, Ninja</creatorcontrib><creatorcontrib>Peterson, Stefan</creatorcontrib><creatorcontrib>Digkas, Evangelos</creatorcontrib><creatorcontrib>Glimelius, Ingrid</creatorcontrib><creatorcontrib>Lagerlöf, Ingemar</creatorcontrib><creatorcontrib>Johansson, Ann-Sofie</creatorcontrib><creatorcontrib>Palma, Marzia</creatorcontrib><creatorcontrib>Hansson, Lotta</creatorcontrib><creatorcontrib>Linderoth, Johan</creatorcontrib><creatorcontrib>Goldkuhl, Christina</creatorcontrib><creatorcontrib>Molin, Daniel</creatorcontrib><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Linköpings universitet</collection><collection>SWEPUB Umeå universitet full text</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Umeå universitet</collection><collection>SwePub Articles full text</collection><jtitle>EJHaem</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wahlin, Bjoern Engelbrekt</au><au>Overgaard, Ninja</au><au>Peterson, Stefan</au><au>Digkas, Evangelos</au><au>Glimelius, Ingrid</au><au>Lagerlöf, Ingemar</au><au>Johansson, Ann-Sofie</au><au>Palma, Marzia</au><au>Hansson, Lotta</au><au>Linderoth, Johan</au><au>Goldkuhl, Christina</au><au>Molin, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged &gt;60 years</atitle><jtitle>EJHaem</jtitle><date>2021</date><risdate>2021</risdate><volume>2</volume><issue>3</issue><spage>400</spage><pages>400-</pages><issn>2688-6146</issn><eissn>2688-6146</eissn><abstract>Treatment for patients &amp;gt; 60 years with classical Hodgkin lymphoma (cHL) is problematic; there is no gold standard, and outcome is poor. Using the Swedish Lymphoma Registry, we analysed all Swedish patients diagnosed with cHL between 2000 and 2014 (N = 2345; median age 42 years; 691 patients were &amp;gt;60 years). The median follow-up time was 6.7 years. Treatment for elderly patients consisted mainly of ABVD or CHOP, and the younger patients were treated with ABVD or BEACOPP (with no survival difference). In multivariable analysis of patients &amp;gt; 60 years, ABVD correlated with better survival than CHOP (p = 0.027), and ABVD became more common over time among patients aged 61-70 years (p = 0.0206). Coinciding with the implementation of FDG-PET/CT, the fraction of advanced-stage disease increased in later calendar periods, also in the older patient group. Survival has improved in cHL patients &amp;gt; 60 years (p = 0.027), for whom ABVD seems superior to CHOP.</abstract><doi>10.1002/jha2.202</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2688-6146 |
| ispartof | EJHaem, 2021, Vol.2 (3), p.400 |
| issn | 2688-6146 2688-6146 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_452094 |
| source | Open Access: Wiley-Blackwell Open Access Journals; PubMed Central |
| subjects | classical Hodgkin lymphoma older patients population-based survival treatment |
| title | Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T19%3A18%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-swepub&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-world%20data%20on%20treatment%20concepts%20in%20classical%20Hodgkin%20lymphoma%20in%20Sweden%202000-2014,%20focusing%20on%20patients%20aged%20>60%20years&rft.jtitle=EJHaem&rft.au=Wahlin,%20Bjoern%20Engelbrekt&rft.date=2021&rft.volume=2&rft.issue=3&rft.spage=400&rft.pages=400-&rft.issn=2688-6146&rft.eissn=2688-6146&rft_id=info:doi/10.1002/jha2.202&rft_dat=%3Cswepub%3Eoai_DiVA_org_umu_228661%3C/swepub%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-s1144-b84351b166988130ce157c67ee04432fd31fb191f5827a41605037560af673ce3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |